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Key Points:  
1. Goal orientated cognitive rehabilitation uses goal setting and evidence-based 
strategies focussing on improving functioning in everyday activities in people with 
dementia.  
2. There are no previous controlled studies of cognitive rehabilitation in dementias 
associated with Parkinson’s. 
3. This pilot randomised controlled trial showed that cognitive rehabilitation was 
superior to treatment-as-usual and relaxation therapy for primary outcomes in 
dementias associated with Parkinson’s.  
4. Cognitive Rehabilitation is feasible and potentially effective for dementias associated 
with Parkinson’s but requires further study.   
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ABSTRACT 
Objective 
To examine the appropriateness and feasibility of cognitive rehabilitation for people with 
dementias associated with Parkinson’s in a pilot randomised controlled study. 
 
Methods 
This was a single-blind pilot randomised controlled trial of goal-oriented cognitive 
rehabilitation for dementias associated with Parkinson’s. After goal setting, participants were 
randomised to cognitive rehabilitation (n=10), relaxation therapy (n=10) or treatment-as-usual 
(n=9). Primary outcomes were ratings of goal attainment and satisfaction with goal attainment. 
Secondary outcomes included quality of life, mood, cognition, health status, everyday 
functioning and carers’ ratings of goal attainment and their own quality of life and stress levels. 
Assessments were at two months and six months following randomisation. 
Results 
At two-months, cognitive rehabilitation was superior to treatment-as-usual and relaxation 
therapy for the primary outcomes of self-rated goal attainment (d = 1.63 and d = 1.82 
respectively) and self-rated satisfaction with goal attainment (d = 2.04 and d = 1.84).   At six-
months, cognitive rehabilitation remained superior to treatment-as-usual (d = 1.36) and 
relaxation therapy (d = 1.77) for self-rated goal attainment.  
Cognitive rehabilitation was superior to treatment as usual and/or relaxation therapy in a 
number of secondary outcomes at two-months (mood, self-efficacy, social domain of quality 
of life, carers’ ratings of participants’ goal attainment) and at six-months (delayed recall, health 
status, quality of life, carer ratings of participants’ goal attainment). Carers receiving cognitive 
rehabilitation reported better quality of life, health status and lower stress than those allocated 
to treatment-as-usual.  
Conclusions  
Cognitive rehabilitation is feasible and potentially effective for dementias associated with 
Parkinson’s disease.   
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INTRODUCTION 
Neuropsychiatric symptoms including cognitive impairment and dementia are common 
features of Parkinson’s disease (PD) 1. Cognitive impairment and PD dementia (PDD) can 
occur at any stage of the disease course 2 but become more prominent as the illness progresses, 
with more than 80% of people living with PD for longer than 20 years meeting criteria for 
dementia 3. Cognitive dysfunction precedes parkinsonian symptoms in Dementia with Lewy 
bodies (DLB) which shares common genetic, neuropathological and neuropsychological 
features with PDD 4 although relationship between the conditions is still subject to debate 5. 
People with PDD and DLB show impairments in various cognitive domains, notably memory, 
visuospatial abilities, attention, planning and reasoning. PDD is a major risk factor for care 
home placement 6 and poses considerable burden upon carers 7. Cognitive impairment in PD is 
associated with reduced functional status 8 and poorer quality of life, as well as poorer quality 
of life for relatives providing care 9, 10. Current treatments for PDD and DLB focus on 
pharmacological interventions which may produce undesirable side-effects and have contra-
indications 11. Non-pharmacological approaches might offer complementary or alternative 
strategies, yet there remains limited research examining cognitive interventions in PD and no 
study has applied these approaches in PDD or DLB 12. A previous systematic review raised 
concerns regarding the scientific rigour of existing studies, and highlighted the lack of 
randomised controlled designs 12. 
 
Cognitive intervention studies in PD without dementia have primarily used cognitive training 
(CT), the guided repeated practice of tasks to target specific cognitive functions. CT may 
provide some benefits to PD patients without dementia for domains of working memory, 
processing speed, and executive functioning, but negligible or no improvements in memory, 
attention, visuospatial abilities, depression, quality of life, and activities of daily living 13. Since 
these latter domains become increasingly impaired as dementia progresses, there is a need to 
develop treatments that can mitigate not only the effects of increasing cognitive decline, but 
also support quality of life and independence. Cognitive rehabilitation (CR) 14 supports people 
with dementia to develop and use evidence-based strategies that compensate for, or reduce the 
impact of, their cognitive and behavioural difficulties, focussing on improving functioning in 
everyday activities. It employs a person-centred approach with assistance from a trained 
therapist to devise and apply meaningful goals, commensurate to the individual’s needs and 
abilities. The strategies employed may be compensatory (using reminders, calendars, alarms) 
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and/or restorative (spaced retrieval learning, mnemonics) depending on the goal selected. 
Similar to CR, cognitive strategy training (CST) also uses an individualised approach using 
strategies to achieve goals relating to daily function. A case-series study of CST for seven 
people with PD without dementia but reporting subjective cognitive decline and self-identified 
functional issues, reported that CST was feasible and potentially effective 15. The study did not 
include people with dementia and thus the application of goal-focussed rehabilitation 
approaches have yet to be applied in PDD and DLB. The efficacy of CR for people with 
Alzheimer’s disease (AD) has previously been indicated in a pilot study 16 and a large multi-
centre randomised controlled trial (RCT) of CR is currently underway to assess its effectiveness 
for people with AD and other dementias excluding PDD and DLB 17.  Recently, we showed 
that people with PDD and DLB were able to engage in goal setting for CR, with goals being 
selected most often in self-management and orientation, medication adherence, learning new 
skills and maintaining social and leisure activities 18.  
The aims of the current study were to examine the appropriateness and feasibility of CR for 
people with PDD and DLB, and explore indications of the treatment’s efficacy relative to an 
active control condition or treatment as usual. Additional aims included assessing the 
usefulness of outcome measures and obtaining effect sizes to inform the development of future 
RCTs of CR in PDD and DLB.  
 
METHODS 
Design 
The Cognitive Rehabilitation for Parkinson’s disease dementia: a pilot randomised controlled 
trial (CORD-PD) was a three-arm, single-blind pilot randomised controlled trial. Ethical 
approval for the study was obtained from the Wales Research Ethics Committee 5 
(13/WA/0340).  The study complied fully with the Declaration of Helsinki. Informed written 
consent was obtained prior to participation.  
Participants 
Potential participants were recruited through Movement Disorder clinics and Memory clinics 
in Betsi Cadwaladr University Health Board (BCUHB), North Wales, UK. Potential 
participants were approached consecutively and invited to an initial screening interview with 
the researcher. Inclusion criteria were a diagnosis of PD according to UK PD Brain Bank 
Diagnostic Criteria 19, a diagnosis of PDD according to Movement Disorder Society consensus 
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criteria 20, 21 or a diagnosis of DLB according to consensus criteria 22 and a score ≤82 on the 
Addenbrooke’s Cognitive Examination–III (ACE-III) 23. Exclusion criteria were a lack of 
stability of prescribed PD medications, cognitive enhancers or psychotropic medication (such 
as substantial additions to medication in the four weeks before the trial or planned changes 
during the period of the trial), other major psychiatric disorder not related to PD, major 
depression, and other significant neurological disease.  
Procedures 
Participants completed baseline demographic, clinical and cognitive assessments and a goal-
setting interview for CR was conducted, as described previously 24, 25. Following the baseline 
visits, participants were randomised to one of the three treatment arms: CR, relaxation therapy 
(RT) or treatment-as-usual (TAU). Post-intervention and follow-up assessments were 
conducted with the researcher two months and six months from randomisation, respectively.  
Interventions 
The CR treatment comprised eight weekly one-hour sessions with the therapist (JR) 25. The 
intervention included the use of evidence-based methods to assist the participant to pursue the 
agreed goals. These methods included compensatory strategies and/or restorative approaches 
to circumvent difficulties relating to orientation, planning, the retention of learned information 
and recall (for examples of goals and strategies used for CR see Supplementary Table 1a). 
Participants were encouraged to practice their strategies between therapy sessions, with the 
assistance of the carer (where available). Carers were invited to participate in the therapy 
sessions to support between-session implementation.  
 
The RT intervention also comprised eight weekly one-hour sessions with the therapist (JR). 
Participants were taught progressive muscle relaxation and breathing exercises in accordance 
with the study’s RT treatment protocol (see Supplementary Table 1b). Participants were 
encouraged to practice these techniques between sessions.  
The TAU arm continued with the standard care available through their healthcare provider.  
Randomisation and blinding 
Following completion of the baseline assessment, participants were randomised to one of the 
CR, RT or TAU arms. Randomisation was conducted by a registered Clinical Trials Unit, the 
North Wales Organisation for Randomised Trials in Health (NWORTH), using a dynamic 
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adaptive sequential randomisation algorithm 26. Allocation to the three groups was achieved 
through stratification on the following variables: diagnosis (PD/DLB), gender, and age (≤69, 
70+). The researcher who collected follow-up data (TJW) was blinded to all randomisation 
outcomes for the duration of the data collection period. After each follow-up assessment, TJW 
completed a form to indicate her beliefs regarding the participant’s group allocation and rated 
her level of certainty regarding this allocation. The trial statistician (AB) and Chief Investigator 
(JVH) remained blind to participant allocations throughout the data collection and analysis 
phases.    
 
Outcomes 
Primary outcomes 
Participants’ ratings for goal attainment and satisfaction with goal attainment from the Bangor 
Goal-Setting Interview (BGSI) 27 were measured at baseline, two-month and six-month  
follow-up assessments. Participants rated their current attainment and satisfaction with their 
attainment for these goals on a scale of 1 – 10, with 1 = unable to carry out or perform 
task/extremely dissatisfied with attainment and 10 = able to carry out or perform task without 
difficulty/extremely satisfied with attainment.  
 
Secondary outcomes  
Baseline and six-month assessments: Participant assessments comprised the Unified 
Parkinson’s Disease Rating Scale (UPDRS) 28 activities of daily living (ADL) and Motor 
domain scores; the modified 11-item Functional Activities Questionnaire (FAQ) 29; the 
Hospital Anxiety and Depression Scale (HADS) 30; Parkinson’s Disease Questionnaire–8 
(PDQ-8) 31; Euroqol Questionnaire-short version (ED5D3L) 32; The World Health 
Organisation Quality of Life Scale – Brief version (WHOQOL-BREF) 33; Generalised Self-
Efficacy Scale (GSES) 34; Delis-Kaplan Executive Function Scale (D-KEFS) Letter Fluency 
subtest 35; D-KEFS Trail Making Test (TMT) 35; Story Recall from the Rivermead Behavioural 
Memory Test-Second Edition (RBMT-II, version A&C) 36; Test of Everyday Attention (TEA, 
version A&C) 37 and the client services receipt inventory (CSRI) 38 to monitor medication 
prescription. Levodopa-equivalent dose (LED) was computed according to standardised 
formulae 39. The carer assessment included the carer ratings for participants’ goal attainment 
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(BGSI); HADS, GSES, WHOQOL-BREF; EQ5D3L; the Neuropsychiatric Inventory 
Questionnaire (NPI-Q) 40 and the Relatives’ Stress Scale (RSS) 41.  
Post-intervention assessment (two-month follow-up): Patient participant assessments 
comprised the HADS; GSES; PDQ-8; WHOQOL-BREF; D-KEFS letter fluency and TMT; 
TEA (version B); Story Recall (RBMT, version B). The carer assessment included the carers’ 
ratings for patients’ goal attainment (BGSI); HADS, GSES, WHOQOL-BREF and the RSS.  
  
Statistical methods 
Analyses were completed for each outcome measure for the two-month and six-month follow-
ups using an ANCOVA model, with baseline scores as covariates, group allocation and 
stratification variables as fixed factors. As this was a pilot study intended to provide 
information that will inform the sample size calculation for a full scale randomised trial no 
formal power calculation was undertaken.  The original published trial design aimed to recruit 
15 in each arm 24, 25.  One of the key objectives of this pilot study was to identify the most 
robust and sensitive outcome measures for development of a larger RCT and therefore due to 
the exploratory nature of this study, Bonferroni corrected p values and confidence intervals 
were deemed too stringent for the purposes of the current analyses. Missing data were imputed 
with mean substitution when a participant did not have a score on a measure but was still 
enrolled in the study for that time point. All statistical tests were two-tailed, and p values less 
than 0.05 were classified as statistically significant. 
 
 
RESULTS 
Recruitment and retention 
The CORD-PD CONSORT diagram is shown in Figure 1. The recruitment rate was 38.8% 
(participants assessed at baseline /potential participants invited – participants not meeting 
inclusion criteria), with 31 participants recruited to the study. The attrition rate following 
randomisation (dropout/randomised) was 14% (4/29). One participant was included in the 
study due to a screening error but was later excluded at baseline. Reasons for withdrawal after 
randomisation were significant deterioration in cognition (n=1) or health-status (n=2) and a 
lack of motivation to continue participation (n=1). Treatment adherence for participants 
randomised to intervention conditions is shown in Supplementary Information Table 2.  
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“Insert figure 1 about here” 
Participants 
At the intervention time point, there were 29 participants with PDD or DLB and 26 carer 
participants. Table 1 shows participant and carer characteristics for the overall sample and 
across treatment groups.  There were no significant differences between these groups on 
baseline measures.  
 
“Insert table 1 about here” 
 
Outcomes  
 
Table 2 shows participants’ outcomes across treatment groups and time points. Mean LED 
estimates for antiparkinsonian medication are also shown.  
 
At the two-month follow-up, analysis showed main effects for participants’ self-rated goal 
attainment (F(1,19) = 8.24 , P = 0.003) and satisfaction with goal attainment (F(1,19) = 10.42, 
P = 0.001) on the BGSI.  
At the six-month follow-up, there were main effects favouring CR for participants’ self-rated 
goal attainment on the BGSI (F(1,18) = 6.39, P = 0.008). Main effects were also found for 
participants’ general health (EQ5D3L, F(1,18) = 5.23, P = 0.02) and quality of life (PDQ8, 
F(1,18) = 5.2, P = 0.02).  
There were no statistically significant differences in mean LED estimates between the baseline 
and six-month follow-up visits for any of the treatment arms (CR: t(6) = 0.67, P = 0.53; TAU: 
t(8) = 0.0, P = 1.0; RT: t(8) = -1.7, P = 0.13). Nine patients were prescribed cholinesterase 
inhibitors and N-methyl-D-aspartate receptor antagonists. Dosages for these drugs at baseline 
and follow-up are shown in Supplementary Information Table 3.   
 
Table 3 shows standardised effect size estimates (d) and confidence intervals for statistically 
significant differences between groups on primary and secondary outcomes for participants.   
“Insert tables 2&3 about here” 
 
Carers 
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Table 4 shows carers’ outcomes across treatment groups and time points. 
Group differences favouring CR were found for carers ratings’ of participants’ goal attainment 
(F(1,15) = 6.44, P = 0.01), carers’ self-ratings for the environmental domain of WHOQOL-
BREF (F(1,15) = 4.41 , P = 0.03) and carers’ self-ratings for overall health using the ED5D3L 
visual analogue (F(1,15) = 3.62, P = 0.05). Table 3 shows standardised effect size estimates 
(d) and confidence intervals for statistically significant differences between groups on carers’ 
outcomes.  
“Insert table 4 about here” 
 
Blinding 
An exact binomial test performed on blinding control data revealed no indications that the 
researcher was able to correctly identify participants’ treatment randomisation allocations at 
either the two-month (9 out of 26 participants correctly identified their group allocation, P = 
1) and six-month (12 out of 25 participants correctly identified their group allocation, P = 0.14) 
assessments.  
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DISCUSSION 
The CORD-PD pilot RCT is the first study to apply goal-oriented CR for dementias associated 
with PD, using an individualised intervention to address goals that are meaningful to the person 
and that take account of the person’s cognitive and functional abilities. People with mild to 
moderate PDD and DLB are able to participate in goal-setting for CR using the BGSI 24 and 
the current results indicate that CR is a feasible and potentially effective intervention for 
individuals with PDD and DLB.  
 
Relative to RT and TAU, participants receiving CR reported significant improvements in goal 
attainment at both the post-intervention and follow-up assessments. CR participants rated their 
satisfaction with their attainment more highly on average than those in either control condition 
at the post-intervention assessment. Analyses of secondary outcomes at two months also 
showed some positive effects for CR in ameliorating depression compared with TAU. Positive 
effects for CR were also found for the social aspects of quality of life when compared with 
TAU and RT, and for self-efficacy when compared with RT. At six months, improved health 
status (as measured by the ED5D3L Index and PDQ8), as well as better performance on a 
delayed recall task, were found for CR compared with TAU. 
 
The CR group reported improvements on goals relating to medication management, planning 
and executing complex tasks (e.g. cooking), learning new skills (e.g. using email) and 
engagement in leisure activities. CR strategies focussing on improving disease management, 
such as medication or therapy adherence, could optimise symptom control in PDD or DLB 
possibly reducing morbidity and health-care costs. CR might enhance or support functioning 
required for everyday activities, reducing the need for institutionalisation and supporting 
community participation. This in turn might reduce isolation and maintain or improve well-
being. Positive effects were obtained with only eight therapy sessions and some effects 
persisted four months after the end of treatment. A longer or more comprehensive treatment, 
perhaps with maintenance sessions in-between assessment visits, might render stronger 
benefits and is worthy of future exploration. One study has suggested that Memantine can lead 
to improvements in goal attainment in PDD 42. It is possible; however, that CR combined with 
pharmacotherapy could provide enhanced benefits. However, prescriptions for anti-
parkinsonian and dementia medications did not differ between groups at baseline or follow-up. 
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At the post-intervention assessment, carer ratings for participants’ attainment were 
significantly higher in the CR than in the RT group, but at follow-up, they were significantly 
higher in the CR than in both the RT and TAU groups. Additionally, carers in the CR group at 
follow-up, reported lower stress levels and higher ratings for overall health and an 
environmental component of quality of life relative to carers in the control groups. It is possible 
that improvements in participants’ attainment are not immediately noticeable to third parties 
until they achieve significant progress with their goals with a reduction in care-related duties 
only at a certain level of independence. 
 
A recent CT trial involving PD patients without dementia demonstrated that improvements to 
specific cognitive functions 43 were maintained one year following treatment and reduced the 
risk of developing cognitive impairment 44. The feasibility of CST for PD patients without 
dementia has also been demonstrated 15. Following on from this work, our results show that 
the benefits of cognitive interventions might extend to patients with more severe cognitive 
impairments seen in PDD and DLB. While CT involves the practice of abstract exercises to 
train cognitive functions, our approach focuses on developing and practicing strategies to assist 
directly with actual daily activities which may be more relevant for people with mild to 
moderate dementia. There is increasing interest in combined treatments in non-
pharmacological research in PD including exercise 45, 46. Avenues for future research could 
include investigating the impact of exercise, CT, and CR, in combination or in comparison with 
each other, on participant outcomes.   
 
Limitations and Future Directions 
One limitation of the current study is the small sample size, which might affect the 
generalisability of these results. Nonetheless, this sample size is typical of pilot psychosocial 
studies in PD 47, 48, 49. Medium to large effects were found in this study in favour of CR relative 
to the control conditions for primary and some secondary outcomes, suggesting that these 
results may be replicated in a larger study. The array of outcome measures is large, increasing 
the likelihood of type-one error inflation. However, a key objective of this study was to assess 
the usefulness of various outcome measures and calculate effect sizes to inform outcome 
selection for a fully-powered trial. DLB participant recruitment was disproportionately small, 
precluding subtype analyses. We did not use a clinical instrument to determine dementia stage 
and instead relied on the clinical judgement. Similarly, we used one measure, the ACE-III 
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global cut-off score, to guide participant selection. Due to the fluctuating nature of cognitive 
impairment apparent in PDD and DLB, such screening methods may have under- or 
overestimated cognitive impairment in some patients. We excluded patients without objective 
cognitive impairment but who may have shown other neuropsychiatric changes (e.g. apathy, 
depression) that could have benefited from this behavioural intervention. Since the emergence 
of neuropsychiatric symptoms is associated with increasing cognitive impairment in PD 50, 
these symptoms might represent prodromal stages of dementia. It would be interesting to 
examine whether CR provides benefits for patients experiencing only behavioural changes, 
such as apathy. Finally, while patients were encouraged to practice or implement strategies 
between CR sessions with carer help, we did not formally monitor practice and cannot assess 
whether the quality, frequency, duration of practice or involvement of a carer between-sessions 
influenced the intervention’s efficacy.  
 
Despite these caveats, the study has several strengths. It adopted the gold-standard RCT 
approach and included an active control condition that gave equal time and attention to 
participants to examine the role of possible placebo effects and other nonspecific variables. 
The study also ensured blinding of researchers to participants’ treatment allocations. CR is 
individualised to the participants’ abilities and priorities, consistent with the preference of 
people living with these conditions for receiving a personalised approach for their difficulties 
51. The results will inform the development of a larger RCT, powered to provide definitive 
evidence for the effectiveness of CR against standard or usual care. The next stages of the 
research will involve consolidating the therapeutic procedures and determining the assessment 
outcomes for a future larger trial which also examines cost-effectiveness alongside multi-
disciplinary care for people with PDD or DLB.  
 
Conclusions 
Despite the negative impacts of PD-related dementia on individuals and their carers, the 
availability of tailored psychosocial treatments remains limited. The CORD-PD pilot study 
contributes to the development of non-pharmacological approaches for cognitive impairment 
in PD, and promotes scientific rigour in this area through the adoption of an RCT design. The 
current results provide primary evidence of the potential effectiveness of goal-oriented CR for 
promoting functional independence in people with PDD and DLB, and improving their well-
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being and that of their carers. Further work is required to evaluate whether this intervention 
can produce benefits in larger cohorts.  
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Table 1. Sample Characteristics at Baseline Assessment 
 
Participants Overall  Treatment Groups * 
Continuous 
variables  
(max score) 
 
N=29 
Mean (SD) 
[Range] 
CR  
N   Mean (SD)[Range] 
RT  
N   Mean (SD)[Range] 
TAU  
N Mean (SD)[Range] 
Age in years 
 
76.34 (6.42) 
[61-85] 
 
10  75.8 (6.61) [61-83] 10  74.9 (6.87) [61-85] 9  78.56 (5.77) [65-84] 
Years of 
education 
 
10.97 (1.55) 
[8-15] 
10  10.9 (1.66) [8-13] 10  11 (1.41) [10-14] 9  11 (1.73) [9-15] 
UPDRS 
Motor (92) 
 
30.28 (9) 
[13-48] 
10   27 (8.74) [13-41] 10  28.2 (7.86) [16-40] 9  36.22 (8.33) [24-48] 
UPDRS ADL 
(52) 
 
17.21 (6.23) 
[4-31] 
10  15.2 (6.58) [4-25] 10  17.7 (5.96) [13-30] 9  18.89 (6.21) [13-31] 
ACE-III 
(100) 
 
71.3 (7.5) 
[52-81] 
10  71.6 (6.74) [60-81] 10  71.9 (7.19) [60 - 81] 9  70.22 (9.38) [52-79] 
NPI-Q 
Severity –
carer rated 
(36) 
 
      N=26 
10.96 (6.96) 
[1-27] 
8    9 (4.34) [4 -17] 10  10.4 (8.91) [1-27] 8  13.62 (6.25) [8-25] 
Categorical 
variables 
 
 CR (n=10) RT (n=10) 
 
TAU (n=9) 
Diagnosis 
PDD/DLB 
 
 
     25/4 
 
9/1 
 
9/1 
 
7/2 
Gender   
M/F 
 
 
     23/6 
                  
8/2 
 
7/3 
 
8/1 
H&Y (%) 
Stage 1 
Stage 1.5 
Stage 2 
Stage 2.5 
Stage 3 
Stage 4 
 
 
4 (13.8) 
1 (3.4) 
6 (20.7) 
5 (17.2) 
10 (34.5) 
3 (10.3) 
 
 
3 (30) 
               0 (0) 
               3 (30) 
               0 (0) 
               3 (30) 
               1 (10)                
 
               0 (0) 
1 (10) 
3 (30) 
2 (20) 
3 (30) 
1 (10) 
 
1 (11) 
0 (0) 
0 (0) 
3 (33.3) 
4 (44.4) 
1 (11.1) 
Carers 
 
Overall Treatment Groups 
Continuous 
variables 
N=26  
Mean (SD) 
[Range] 
 
CR (n=8) 
   Mean (SD)[Range] 
RT (n=10) 
   Mean (SD)[Range] 
TAU (n=8) 
   Mean (SD)[Range] 
Age in years 
 
70.5 (10.52) 
[44-85] 
 
   67 (9.47) [53-78]    70.5 (8.28) [58-80]    74 (13.75) [44-85] 
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Years of 
education 
 
11.42 (1.63) 
[9-14] 
 
   11.62 (1.3) [10-14]    12 (1.83) [10-14]    10.5 (1.41) [9-12] 
Categorical 
variables 
 
 CR (n=8) RT (n=10) 
 
TAU (n=8) 
Gender  
M/F 
 
 
5/21 
 
1/7 
 
3/7 
 
1/7 
Relationship 
Spouse/Child 
 
 
23/3 
 
7/1 
 
9/1 
 
7/1 
Note: Higher scores indicate greater performance/higher ratings except for NPI Severity where higher scores 
indicate greater symptomatology. UPDRS, Unified Parkinson’s Disease Rating Scale; ADL, activities of daily 
living; ACE-III, Addenbrooke’s Cognitive Examination – Third Edition; NPI-Q, Neuropsychiatric Inventory-
Questionnaire; PDD, Parkinson’s disease dementia; DLB, Dementia with Lewy bodies; H&Y, Hoehn & 
Yahr; M, Male; F, Female. CR, Cognitive rehabilitation;   RT, relaxation therapy; TAU treatment as usual. 
* There were no significant differences between these groups on baseline measures.  
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Table 2 Participant outcomes and mean LED estimates across assessment time points  
 
 Baseline 
 
Post intervention Follow-up 
Measures 
(max score) 
 
Arm N Mean (SD) [Range] 
 
N Mean (SD) [Range] N Mean (SD) [Range] 
BGSI 
Attainment 
(10)  
 
CR 
RT 
TAU 
10  3.08 (1.43) [1-5.33] 
10  3.17 (1.3) [1-5] 
9    2.91 (1.27) [1.33-5] 
8  6.29 (1.44) [3-8] 
9  3.64 (1.32) [2-6] 
9  3.69 (2.3) [1-8] 
7  6.6 (1.93) [4-9.5] 
9  3.59 (1.93) [1-6.5] 
9  4.02 (2.38) [1-8] 
BGSI 
Satisfaction 
(10) 
 
CR 
RT 
TAU 
10  3.3 (1.36) [1-5] 
10 4.13 (1.39) [2-6.67] 
9    2.69 (1.14) [1-4.5] 
8  6.54 (1.48) [4.3 – 9] 
9  4.06 (0.8) [2.5-5] 
9  3.44 (1.9) [1-6.3] 
7  5.98 (1.7) [4.33-8.33] 
9  4.57 (1.45) [2-7.5] 
9  4.31 (2.54) [1-8] 
BGSI  
Attainment 
carer-rated 
(10) 
 
CR 
RT 
TAU 
8    2.35 (0.99) [1-4] 
8    2.35 (1.39) [1-5.33] 
8    2.04 (1.06) [1-4] 
6  4.89 (2.53) [2-8.33] 
9  2.94 (1.46) [1-5.33] 
8  3.01 (2.59) [1-8.67] 
5  4.83 (2.44) [2.3-7.7] 
9  2.59 (1.67) [0.7 - 5.3] 
8  2.10 (1.95) [1-6.67] 
HADS 
Depression 
(21) 
 
CR 
RT 
TAU 
10  9.13 (1) [2-16] 
10  6.5 (3.54) [1-11] 
9    9.13 (4) [2-16] 
8  5.5 (3.5) [1-11] 
9  6.22 (3.31) [1-10] 
9  10.22 (4.09) [3-17] 
7  6.14 (4.14) [1-12] 
9  6.67 (3.67) [1-10] 
9  8.11 (4.01) [2-14] 
HADS 
Anxiety (21) 
 
CR 
RT 
TAU 
10  7.2 (3.8) [0-11] 
10  5.8 (2.97) [0-8] 
9   10.7 (4.97) [2-19] 
 
8  6.38 (3.54) [0-10] 
9  6.89 (3.55) [1-12] 
9  10.56 (5.08) [4-21] 
7  5.29 (2.69) [3-9] 
9  6.56 (3.21) [1-10] 
9  10.33 (4.3) [3-17] 
ED5D3L 
Index (1.0) 
  
CR 
RT 
 
TAU 
10  0.65 (0.27) [0.06-1]  
10  0.66 (0.18) [0.19-
0.84] 
9   0.35 (0.31) [-0.02-
0.71] 
 
 
 
        Not measured 
7  0.59 (0.31) [-0.16-1] 
9  0.56 (0.31) [0.19-
0.85] 
9  0.13 (0.26) [-0.07-
0.64] 
 
ED5D3L 
VAS (100) 
 
CR 
RT 
TAU 
10  65 (15.09) [40-90] 
10  65.5 (14.99) [50-90] 
9   56.1 (13.18) [35-70] 
 
 
Not Measured 
7  67.86 (17.53) [50-90] 
9  57.22 (18.56) [30-80] 
9  46.11 (17.82) [10-70] 
PDQ8 (100) 
 
CR 
 
RT 
 
TAU 
10  21.56 (15.27) [3.1-
40.6] 
10  30 (12.34) [9.4-
46.9) 
9  40.28 (12.74) [18.8 -
52.5] 
 
8  29.3 (10.95) [9.38-
40.63] 
9  31.94 (10.34) [16.63-
46.88] 
9  47.57 (16.3) [31.25-
78.13] 
7  26.18 (16.1) [6.25-
53.13] 
9  26.39 (14.07) [9.38-
53.13] 
9  54.51 (16.69) [31.25-
81.25] 
WHOQOL-
BREF 
Physical (20) 
 
CR 
RT 
TAU 
10  13.2 (2.57) [9-18] 
10  12 (2.4) [9-16] 
7   10.29 (3.35) [6-15] 
 
8  12.5 (3.12) [7-18] 
9  12.33 (1.87) [9-15] 
9  10.26 (2.69) [5-14] 
7  13.15 (2.1) [10-17] 
9  13.33 (2.83) [8-17] 
9  11.67 (2.28) [8-16] 
WHOQOL-
BREF Psych. 
(20) 
 
CR 
RT 
TAU 
10  14.5 (2.22) [13-20] 
10  12.6 (1.96)[9-15] 
7    11.57 (2.07) [9-14] 
8  13.25 (2.82) [10-18] 
9  12.44 (2.13) [10-16] 
9  10.44 (2.79) [5-15] 
7  14.49 (2.65) [11-19] 
9  13.33 (2.5) [10-17] 
9  12.82 (1.1) [10-3.47] 
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WHOQOL-
BREF Social 
(20) 
 
CR 
RT 
TAU 
10  14.4 (3.92) [8-20] 
10  15.8 (3.49) [7-19] 
7   14.86 (4.06) [11-20] 
8  15.85 (2.31) [12-19] 
9  14.78 (3.27) [9-20] 
9  14.06 (4.30) [7-20] 
7  15.47 (2.02 [14.4-20] 
9  14.56 (4.12 [8-19] 
9  13.47 (3.5) [5-16]   
WHOQOL-
BREF 
Environ. (20) 
 
CR 
RT 
TAU 
10  15.7 (2.54) [11-20] 
10  15.9 (2.02) [13-19] 
7    15.43 (2.51) [12-19] 
 
8  16.13 (2.23) [13-19] 
9  15.33 (1.22) [14-17] 
9  14.99 (2.38) [12-19] 
7  15.98 (1.49) [14-18] 
9  15.67 (1.8) [13-18] 
9  15.32 (2.22 [12-19] 
FAQ (33) 
 
CR 
RT 
TAU 
10   9.5 (7.04) [2-24] 
10   8.6 (6.57) [2-25] 
9     15.33 (4.92) [8-24] 
 
 
Not measured 
7  13.57 (7.87) [0-25] 
9  13.44 (8.29) [3-28] 
9  17 (8.59) [4-27] 
GSES (40) 
 
CR 
RT 
TAU 
9    31 (4.15) [25-38] 
10  31.1 (5.43) [21-39] 
9    27.89 (4.46) [18-35] 
 
8  31.5 (4.24) [27-37] 
9  28.22 (5.56) [18-39] 
9  28.86 (2.5) [25-32] 
 
7  31.83 (5.07) [26-39] 
9  28.64 (4.87) [18-37] 
9  26.87 (2.4) [23-29] 
D-KEFS 
Fluency (tot. 
corr. resp.) 
 
CR 
RT 
TAU 
10  27.4 (11.83) [7-47] 
10  29.1 (12.45) [11-51] 
9    23.89 (10.73) [7-46] 
 
8  30.13 (14.4) [7-54] 
9  31.44 (10.4) [16-48] 
9  24.67 (13.82) [8-53] 
7  23.14 (7.58) [9-31] 
9  31.44 (12.2) [17-54] 
9  24 (11.38) [7-43] 
TEA No 
distraction (7) 
 
CR 
RT 
TAU 
10   5.9 (1.29) [3-7] 
10   6.4 (1.07) [4-7] 
9     5.56 (1.51) [3-7] 
8  6 (1.2) [4-7] 
9  6.44 (0.53) [6-7] 
9  5.44 (2.56) [0-7] 
7  5.86 (0.9) [5-7] 
9  6.33 (1) [4-7] 
9  4.33 (2.74) [0-7] 
TEA 
Distraction 
(10) 
 
CR 
RT 
TAU 
10   3.9 (1.79) [1-6] 
10   7 (2.21) [3-9] 
8     6 (3.42) [1-9] 
8  4.64 (2.33) [2-9] 
9  5.22 (3.8) [1-10] 
9  5.13 (2.89) [1-10] 
7  3.06 (1.82) [1-5.22] 
9  7.22 (3.96) [0-10] 
9  4.8 (3.9) [0-10] 
 
D-KEFS 
TMT 
Switching 
Scaled score 
(19)  
  
CR 
RT 
TAU 
3     4.33 (3.21) [2-8] 
6     4.83 (2.93) [2-9] 
5     4.2 (1.92) [2-7]  
 
3  4 (3.46) [2-8] 
3  6.67 (4.04) [2-9] 
3  3.67 (1.12) [3-5] 
 
 
2  4.5 (2.1) [3-6] 
4  2 (0.82) [1-3] 
3  4.67 (2.89) [3-8] 
RBMT 
Immediate 
memory  
recall (21) 
 
CR 
RT 
TAU 
10   3.45 (2.13) [1-8.5] 
10   3.3 (2.32) [1.5-8.5] 
9     3.5 (2.14) [1-8] 
8  4.38 (1.58) [2.5-7.5] 
9  3.72 (3.1) [0.5-10.5] 
9  3.94 (1.79) [1.5-7] 
7  3.43 (2.15) [0-7] 
9  3.33 (0.97) [2-4.5] 
9  3.06 (1.63) [0.5-5] 
RBMT 
Delayed 
memory 
recall (21) 
 
CR 
RT 
TAU 
10  1.7 (2.46) [-1-6.5] 
10  1.45 (1.5) [-0.5-3.5] 
9    1.33 (1.58) [1-3.5] 
8  2.17 (1.36) [0-3.5] 
9  2.33 (2.45) [-1-6.5] 
9  2.39 (1.85) [-1-4.5] 
7  3.06 (1.57) [1.5-5.5] 
9  2 (1.85) [-1-4.5] 
9  0.99 (1.27) [-1-2.5] 
 
LED 
estimates 
    
LED estimate 
(mgs.) 
CR 
 
RT 
 
TAU 
7     635 (62734) [150-
1950] 
9     533.3 (391.7) [0 -
1080] 
9     588.1 (679.4) [0-
2273] 
 
 
         Not Measured 
7  503.4 (430.2) [150-
1360] 
9  600 (459.7) [0-1420] 
 
9  588.1 (671) [0-2273] 
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Significant results in bold- see table 3 for effect sizes. 
Note: For all measures, higher scores indicate greater performance or higher ratings except for HADS  
Depression, HADS Anxiety, PDQ8 and FAQ where higher scores indicate lower performance or greater 
symptomatology. BGSI, Bangor Goal Setting Interview; HADS, Hospital Anxiety and Depression 
Scale;  ED5D3L,  Euroqol Questionnaire-short version;  VAS, visual analogue scale; PDQ8, Parkinson’s 
Disease Questionnaire–8;  WHOQOL-BREF, World Health Organisation Quality of Life Scale – Brief 
version; Psych., Psychological; Environ., Environmental; FAQ, Functional Activity Questionnaire; 
GSES, Generalised Self-Efficacy Scale; TEA, Test of Everyday Attention; D-KEFS, Delis-Kaplan 
Executive Function Scale; tot., total; corr., correct; resp., responses; TMT, Trial Making Test; RBMT, 
Rivermead Behavioural Memory Test; LED, Levodopa-dose Equivalent; mgs., Milligrams.  CR, 
Cognitive rehabilitation;   RT, relaxation therapy; TAU treatment as usual.      
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Table 3   Standardised effect size estimates (d) and confidence intervals for statistically 
significant differences (p<0.05) on primary and secondary outcomes 
 
Measures Post-intervention (two months) Follow-up (six months)  
 Comparison    d (95% CI)               P 
 
Comparison     d (95% CI)                 P 
Primary 
BGSI 
Attainment 
 
CR vs. TAU   1.63 (0.53-2.73)      .004 
CR vs. RT      1.82 (0.69-2.95)      .002 
 
CR vs. TAU    1.36 (0.27-2.46)       .015 
CR vs. RT       1.77 (0.61-2.93)       .003 
BGSI 
Satisfaction  
 
CR vs. TAU   2.04 (0.87-3.22)      .001 
CR vs. RT      1.84 (0.7-2.97)        .002 
 
 
No statistically significant differences 
Secondary - Participants 
BGSI 
Attainment 
carer rated 
 
CR vs. RT      1.19 (0.07-2.31)      .039 
 
CR vs. TAU    1.89 (0.55-3.22)       .005 
CR vs. RT       1.77 (0.5-3.05)         .007 
HADS 
Depression  
 
CR vs. TAU   -1.22 (-2.26- -0.18) .027 
 
No statistically significant differences 
GSES  CR vs. RT      1.07 (0.06-2.09)      .041 
 
No statistically significant differences 
WHOQOL-
BREF Social 
CR vs. TAU   1.11 (0.09-2.14)      .039 
CR vs. RT      1.13  (0.1-2.16)       .037 
 
 
No statistically significant differences 
ED5D3L 
Index 
 
                  Not measured 
CR vs. TAU    1.74 (0.59-2.9)         .007 
RT vs. TAU    1.53 (0.48-2.58)       .016 
 
PDQ8   
No statistically significant differences 
CR vs. TAU   -1.43 (-2.53- -0.32)   .033 
RT vs. TAU   -1.65 (-2.72- -0.58)   .006 
 
RBMT 
Delayed 
memory recall 
 
 
No statistically significant differences 
CR vs. TAU    1.26 (0.18-2.34)       .025 
Secondary- Carers  
 
HADS 
Anxiety 
 
RT vs. TAU  -1.12 (-2.14- -0.09)   .044        No statistically significant differences 
ED5D3L VAS                      Not Measured CR vs. TAU     1.41 (0.17-2.65)      .028 
CR vs. RT        1.33 (0.13-2.53)      .038 
 
WHOQOL-
BREF Psych.  
 
No statistically significant differences CR vs. RT        1.41 (0.2-2.63)        .029 
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WHOQOL-
BREF 
Environ. 
  
No statistically significant differences CR vs. TAU     1.71 (0.41-3.01)      .01 
CR vs. RT        1.21 (0.02-2.39)      .053 
RSS No statistically significant differences CR vs. TAU    -1.42 (-2.6 - -0.18)   .027 
 
Note: A positive effect size indicates that the first group is greater/higher than second group; a 
negative effect sign indicates the second group is greater/higher than the first group (for HADS 
Depression and Anxiety, PDQ8 and the RSS, higher scores indicate lower well-being or greater 
symptomatology). BGSI, Bangor Goal Setting Interview; HADS, Hospital Anxiety and Depression 
Scale; GSES, Generalised Self-Efficacy Scale; WHOQOL-BREF, World Health Organisation Quality 
of Life Scale – Brief version; Psych., Psychological; Environ., Environmental ED5D3L,  Euroqol 
Questionnaire-short version; PDQ8, Parkinson’s Disease Questionnaire–8; RBMT, Rivermead 
Behavioural Memory Test; ED5D3L, Euroqol Questionnaire-short version;  VAS, visual analogue 
scale; RSS, Relative’s Stress Scale.  CR, Cognitive rehabilitation;   RT, relaxation therapy; TAU 
treatment as usual. 
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Table 4 Carers’ outcomes across assessment time points  
 
 Baseline 
 
Post intervention Follow-up 
Measures 
(max score) 
 
Arm N Mean (SD) [Range] 
 
N Mean (SD) [Range] N Mean (SD) [Range] 
HADS 
Depression 
(21) 
 
CR 
RT 
TAU 
8    3.5 (2.78) [0-8] 
10  4.4 (2.59) [0-8] 
8    8 (4) [1-9] 
6  3 (3.69) [0-9] 
9  4.67 (2.78) [1-8] 
8  4.38 (3.02) [1-11] 
5  2.8 (3.03) [1-8] 
9  5.89 (3.28) [1-12] 
8  5.38 (3.11) [2-10] 
HADS 
Anxiety (21) 
 
CR 
RT 
TAU 
 
8    8 (4.13) [0-8] 
10  4.8 (3.01) [0-11] 
8    6.5 (2.98) [3-11] 
 
6  4.5 (2.17) [1-7] 
9  4.44 (3.21) [0-10] 
8  7.57 (3.41) [5-15] 
5  5.8 (2.94) [3-9] 
9  6.53 (4) [1-13] 
8  8.13 (4.76) [4-17] 
ED5D3L 
Index (1.0) 
  
CR 
RT 
TAU 
 
8    0.92 (0.11) [0.73-1] 
10  0.8 (0.19) [0.52-1] 
8    0.69 (0.27) [0.09-1] 
 
Not Measured 
5  0.75 (0.24) [0.36-1] 
9  0.77 (0.15) [0.62-1] 
8  0.7 (0.69) [0.62-0.85] 
ED5D3L 
VAS (100) 
 
CR 
RT 
TAU 
 
8    76.9 (14.13) [50-90] 
10  82 (12.29) [65-100] 
8    67.8 (14.31) [50-90] 
 
Not Measured 
5  84 (8.94) [70-90] 
9  71.1 (20.43) [45-100] 
8  54.13 (28.5) [3-90] 
WHOQOL-
BREF 
Physical (20) 
 
CR 
RT 
TAU 
8    16.75 (1.83) [13-18] 
10  15.8 (3.61) [9-19] 
8    14.12 (2.53) [10-18] 
6  16.83 (1.17) [15-18] 
9  14.7 (4.36) [8-19] 
8  14.25 (2.19) [10-17] 
5  16.6 (2.07) [14-19] 
9  14.1 (3.66) [10-19] 
8  14.2 (2.3) [10-18] 
WHOQOL-
BREF Psych. 
(20) 
 
CR 
RT 
TAU 
8    16.75 (1.39) [15-19] 
10  16 (2.75) [11-19]   
8    14.5 (2) [11-17] 
6  16 (2.83) [11-19] 
9  15.89 (2.93) [10-19] 
8  14.63 (1.6) [12-17] 
5  17 (1.58) [15-19] 
9  14.56 (1.81) [12-17] 
8  14.37 (1.68) [11-16] 
WHOQOL-
BREF Social 
(20) 
 
CR 
RT 
TAU 
8    16 (2.51) [12-20] 
10  14.9 (15) [12-19] 
8    15.12 (2.42) [11-19] 
6  14.33 (2.34) [12-17] 
9  15.22 (3.46) [11-20] 
8  14.75 (1.83) [12-17] 
5  15.2 (5.22) [8-20] 
9  15.3 (2.5) [11-20] 
8  14.6 (1.4) [13-16] 
WHOQOL-
BREF 
Environ. (20) 
 
CR 
RT 
TAU 
8    17.12 (1.36) [15-18] 
10  16.7 (1.49) [14-19] 
8    16.38 (2.88) [10-19] 
6  17.2 (2.99) [13-20] 
9  15.89 (2.09) [12-18 
8  15.75 (2.55) [10-18] 
5  18.4 (1.34) [17-20] 
9  16.2 (1.97) [14-20] 
8  15.42 (2.34) [10-18] 
GSES (40) 
 
CR 
RT 
TAU 
 
8    33.5 (4.31) [28-40] 
10  33.6 (4.06) [27-38] 
8    31.12 (5.33) [24-39] 
6  33.5 (3.67) [30-38] 
9  32.67 (5.34) [26-40] 
8  32.13 (4.42) [25-39] 
5  36 (4.3) [30-40] 
9  32.33 (5.55) [26-40] 
8  31.88 (4.39) [56-38] 
RSS (60) 
 
CR 
RT 
TAU 
8    17.75 (11.16) [5-35] 
10  22.7 (8.93) [6-37] 
8    22.12 (7.7) [8-34] 
6  19.83 (13.94) [4-41] 
9  21.44 (7.18) [10-30] 
8  25 (8.91) [11-37] 
5  16.2 (10.89) [4-27] 
9  22.69 (10.5) [6-35] 
8  9.68 (3.87) [5-16] 
NPI-Q 
Distress (60) 
 
CR 
RT  
TAU 
8    6 (4.81) [0-16] 
10  9.4 (9.97) [0-29]  
8    14 (9.9) [5-33]  
 
Not Measured 
5  10.8 (14.79) [0-36] 
9  7.11 (5.42) [0-15] 
8  10 (4.81) [1-16] 
 
Significant results in Bold- see table 3 for effect sizes.  
Note: For all measures, higher scores indicate greater performance or higher ratings except for HADS  
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Depression, HADS Anxiety, RSS and NPI Distress where higher scores indicate lower well-being or 
greater symptomatology.  HADS, Hospital Anxiety and Depression Scale;  ED5D3L,  Euroqol 
Questionnaire-short version;  VAS, visual analogue scale; WHOQOL-BREF, World Health 
Organisation Quality of Life Scale – Brief version;  Psych., Psychological; Environ., Environmental; 
GSES, Generalised Self-Efficacy Scale; RSS, Relatives’ Stress Scale;  NPI-Q, Neuropsychiatric 
Inventory-Questionnaire. CR, Cognitive rehabilitation;   RT, relaxation therapy; TAU treatment as 
usual.  
